Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.

Trial Details

NCT ID
NCT04894643
Phase
NA
Sponsor
EBG MedAustron GmbH
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Proton Ions
  • Nab-PACLitaxel
  • Gemcitabine
  • Capecitabine
  • Surgical resection of the pancreas (when feasible)
Locations (sample)
  • Wiener Neustadt, Lower Austria, Austria|47.80485,16.23196
  • Wiener Neustadt, Austria|47.80485,16.23196

Key Eligibility Criteria

  • Patients with histologically or cytologically confirmed diagnosis of pancreatic cancer
  • Diagnosis of borderline resectable cancer according to the international consensus definition 2017.
  • Negative staging for distant metastasis
  • Blood test within the following limits absolute neutrophil count \> 1,500 cells/mm³, platelet count \> 100,000 cells/mm³, Aspartate Aminotransferas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →